NanoRepro AG
XETRA NN6.DE
NanoRepro AG Debt to Equity Ratio for the year ending December 31, 2023: 0.00
-
NanoRepro AG Debt to Equity Ratio for the year ending December 31, 2022 was 0.00, a -100.00% change year over year.
-
NanoRepro AG Debt to Equity Ratio for the year ending December 31, 2021 was 0.00, a -98.46% change year over year.
-
NanoRepro AG Debt to Equity Ratio for the year ending December 31, 2020 was 0.17, a 278.11% change year over year.
-
NanoRepro AG Debt to Equity Ratio for the year ending December 31, 2019 was 0.04, a 105,662.78% change year over year.
| Date | Debt to Equity Ratio | Debt to Income Ratio | Debt to Tangible Net Worth Ratio | Dividend Coverage Ratio |
|---|
Don’t Miss A Beat
| CEO | Ms. Lisa Jungst |
| IPO Date | Oct. 22, 2009 |
| Location | Germany |
| Headquarters | Untergasse 8 |
| Employees | 22 |
| Sector | Consumers Staples |
| Industries | |
NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.
Past 5 years
USD 17.64
StockViz Staff
February 6, 2025
Any question? Send us an email